Regulus Therapeutics, Inc. (RGLS)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Regulus Therapeutics, Inc. (RGLS)
Go deeper and ask any question about RGLS
Company Performance
Current Price
as of Sep 13, 2024$1.61
P/E Ratio
N/A
Market Cap
$105.4M
Description
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.
Metrics
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerRGLS
- Price$1.61+1.90%
Trading Information
- Market Cap$105.40M
- Float80.79%
- Average Daily Volume (1m)296,644
- Average Daily Volume (3m)797,262
- EPS-$1.26
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$11.04M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$12.17M
- EV$21.98M
- EV/RevenueN/A
- P/EN/A
- P/SN/A